Effect of a Third COVID-19 Booster Among Health Care Workers
NCT05373459 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3167
Last updated 2024-02-28
Summary
A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals.
HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.
Conditions
- COVID-19 Vaccines
Interventions
- BIOLOGICAL
-
Third COVID-19 booster
Third COVID-19 booster
Sponsors & Collaborators
-
Hong Kong Sanatorium & Hospital
lead INDUSTRY
Principal Investigators
-
Jonpaul Sze Tsing Zee, MBChB · Hong Kong Sanatorium & Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-05-16
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
Countries
- Hong Kong
Study Locations
More Related Trials
-
The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines
NCT00792610 ·Status: COMPLETED ·Phase: NA
-
Antigen-specific Immune Response to Hepatitis B Virus in Utero
NCT00845403 ·Status: UNKNOWN
-
Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19
NCT04496141 ·Status: COMPLETED
-
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
NCT05204602 ·Status: UNKNOWN
-
Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19
NCT05303103 ·Status: COMPLETED
-
Efficacy of Hepatitis B Vaccine Boosters Among Neonatally Vaccinated Children in Chongqing
NCT03867643 ·Status: RECRUITING
-
Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.
NCT05774418 ·Status: COMPLETED
-
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
NCT03063723 ·Status: COMPLETED
-
Dose of Hepatitis B Vaccines in Non/Low-response Populations
NCT01564134 ·Status: COMPLETED ·Phase: NA
-
Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory
NCT05376124 ·Status: RECRUITING
-
The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication
NCT02038088 ·Status: COMPLETED
-
Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells
NCT04032392 ·Status: UNKNOWN ·Phase: PHASE1
-
Quality of Life and Health Utility of Patients With CHB Infections
NCT03329820 ·Status: COMPLETED
-
Risk Factors and Characteristics of COVID 19 Infection in Patients With Haematological Diseases
NCT04930731 ·Status: UNKNOWN
-
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
NCT00147459 ·Status: UNKNOWN ·Phase: NA
-
Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, Wuhan
NCT05767294 ·Status: ENROLLING_BY_INVITATION
-
Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study
NCT01502397 ·Status: COMPLETED
-
Liver Injury After COVID-19 Vaccination
NCT05470894 ·Status: COMPLETED
-
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China
NCT07075029 ·Status: NOT_YET_RECRUITING
-
COVID-19 Vaccines in Patients With Chronic Liver Disease
NCT05017805 ·Status: UNKNOWN ·Phase: NA
-
Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection
NCT06966908 ·Status: RECRUITING
-
Antibody Response to COVID-19 Vaccines in Liver Disease Patients
NCT04775069 ·Status: COMPLETED ·Phase: PHASE4
-
Humoral and Cellular Response in Shift Workers
NCT01528280 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity of the Hepatitis B Vaccine
NCT04540653 ·Status: UNKNOWN ·Phase: PHASE4
-
Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents
NCT00141999 ·Status: COMPLETED